AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
GALLEX 9: Safety and Tolerability of Oral Tesaglitazar When Added to Insulin Therapy in Patients With Type 2 Diabetes
Phase 3
Terminated
- Conditions
- First Posted Date
- 2005-09-30
- Last Posted Date
- 2010-11-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 270
- Registration Number
- NCT00229710
- Locations
- 🇺🇸
Research Site, Madison, Wisconsin, United States
An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-30
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1297
- Registration Number
- NCT00229658
- Locations
- 🇺🇸
Research Site, Milwaukee, Wisconsin, United States
Effect of Iressa With/Without Concurrent Chemoradiotherapy on Tumor Gene Expression Profiles in Patients With Advanced Non-Nasopharyngeal Head and Neck Carcinoma
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-29
- Last Posted Date
- 2007-12-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT00228488
Relapse Prevention, RoW: Study to Evaluate Prevention of Relapse in Patients in Stable Chronic Schizophrenia Receiving Either Seroquel or Placebo
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-29
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 197
- Registration Number
- NCT00228462
- Locations
- 🇵🇱
Investigative Site, Tuszyn, Poland
A Study to Assess the Concentration of Budesonide in Breast Milk From Asthmatic Women
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-29
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 8
- Registration Number
- NCT00228475
Esomeprazole for Treatment of GERD in Pediatric Patients
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-29
- Last Posted Date
- 2010-11-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT00228527
- Locations
- 🇮🇹
Research Site, Napoli, Italy
Dutch Sub Study: Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA). PET Sub Study
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-29
- Last Posted Date
- 2010-11-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT00228514
- Locations
- 🇳🇱
Research Site, Groningen, Netherlands
TROPHY - Candesartan Cilexetil Long-term Hypertension Prevention Trial
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-28
- Last Posted Date
- 2011-08-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1000
- Registration Number
- NCT00227318
- Locations
- 🇺🇸
Research Site, Milwaukee, Wisconsin, United States
Quetiapine Fumarate (SEROQUEL) in the Treatment of Adolescent Patients With Schizophrenia and Bipolar I Disorder
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-28
- Last Posted Date
- 2013-01-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 381
- Registration Number
- NCT00227305
- Locations
- 🇺🇦
Research Site, Odessa, Ukraine
GALLEX 6: Study to Evaluate the Safety and Tolerability of Tesaglitazar in Patients With Type 2 Diabetes Mellitus
Phase 3
Terminated
- Conditions
- First Posted Date
- 2005-09-27
- Last Posted Date
- 2010-11-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1100
- Registration Number
- NCT00226330
- Locations
- 🇬🇧
Research Site, Wiltshire, United Kingdom
© Copyright 2024. All Rights Reserved by MedPath